ArticleBritish journal of cancer2008
Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma.
Article in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.British journal of cancer · 2015Pooled it
- Systematic review of c-met as a prognostic indicator in esophageal cancer patients: a meta-analysis study.Discover oncology · 2025Article
- Proteomic characterization of MET-amplified esophageal adenocarcinomas reveals enrichment of alternative splicing- and androgen signaling-related proteins.Cellular and molecular life sciences : CMLS · 2025Article
- EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.Journal of gastrointestinal oncology · 2016Article
- The tumor microenvironment in esophageal cancer.Oncogene · 2016Review
- miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression.International journal of molecular medicine · 2016Article
- c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target.BMC cancer · 2015Article
- Article
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.Oncotarget · 2014Article
- Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis.Journal of gastrointestinal oncology · 2014Article
- Role of met axis in head and neck cancer.Cancers · 2013Article
- Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction.Cancer biology & therapy · 2013Review
- Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.The oncologist · 2013Article
- Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia.Journal of cell science · 2012Article
- Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer in vitro and in vivo.Acta pharmacologica Sinica · 2012Article
- MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.British journal of cancer · 2011Article
- Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?World journal of gastroenterology · 2011Article
- Molecular imaging for guiding oncologic prognosis and therapy in esophageal adenocarcinoma.Hospital practice (1995) · 2011Review
- Prognostic role of c-met expression in breast cancer patients.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2011Article
- Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.Journal of signal transduction · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oesophageal adenocarcinoma is an aggressive malignancy with propensity for early lymphatic and haematogenous dissemination. Since conventional TNM staging does not provide accurate prognostic information, novel molecular prognostic markers and potential therapeutic targets are subject of intense research. The aim of the present study was to study the prognostic significance of Met, the hepatic growth factor (HGF) receptor and a possible target for therapy in comparison to cyclooxygenase-2 (COX-2). Tumour sections from 145 consecutive patients undergoing intentionally curative surgery for oesophageal adenocarcinoma were immunohistochemically analysed for Met and COX-2 expression. Clinicopathological data were prospectively collected for all patients. Patients with high Met expression had significantly reduced overall and disease-specific 5-year survival rates (P< or =0.001 and P< or =0.001, respectively) and were more likely to develop distant metastases (P=0.002) and local recurrences (P=0.004) compared to patients with low Met expression. High COX-2 expression tended to be correlated with poor long-term survival but this did not reach statistical significance. Expression of Met was recognised as a significant and independent prognostic factor by stage-specific analysis and multivariate analysis (relative risk=2.3; 95% CI=1.3-4.1). These findings support the importance of Met in oesophageal adenocarcinoma and support the concept of Met tyrosine kinase inhibition as (neo-) adjuvant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.